<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=utf-8">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 15">
<meta name=Originator content="Microsoft Word 15">
<link rel=File-List href="AKBA%203E.fld/filelist.xml">
<link rel=Edit-Time-Data href="AKBA%203E.fld/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Microsoft Office User</o:Author>
  <o:LastAuthor>Microsoft Office User</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>5</o:TotalTime>
  <o:Created>2019-04-26T20:26:00Z</o:Created>
  <o:LastSaved>2019-04-26T20:26:00Z</o:LastSaved>
  <o:Pages>5</o:Pages>
  <o:Words>1209</o:Words>
  <o:Characters>6896</o:Characters>
  <o:Lines>57</o:Lines>
  <o:Paragraphs>16</o:Paragraphs>
  <o:CharactersWithSpaces>8089</o:CharactersWithSpaces>
  <o:Version>16.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData href="AKBA%203E.fld/themedata.thmx">
<link rel=colorSchemeMapping href="AKBA%203E.fld/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>JA</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:UseWord2010TableStyleRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" DefPriority="99"
  LatentStyleCount="375">
  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 9"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="header"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footer"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index heading"/>
  <w:LsdException Locked="false" Priority="35" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of figures"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope return"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="line number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="page number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of authorities"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="macro"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="toa heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 5"/>
  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Closing"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Signature"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="true"
   UnhideWhenUsed="true" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Message Header"/>
  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Salutation"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Date"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Note Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Block Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="FollowedHyperlink"/>
  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Document Map"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Plain Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="E-mail Signature"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Top of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Bottom of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal (Web)"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Acronym"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Cite"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Code"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Definition"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Keyboard"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Preformatted"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Sample"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Typewriter"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Variable"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation subject"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Balloon Text"/>
  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" QFormat="true"
   Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" QFormat="true"
   Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" QFormat="true"
   Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" QFormat="true"
   Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" QFormat="true"
   Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" QFormat="true"
   Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" SemiHidden="true"
   UnhideWhenUsed="true" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Grid Table Light"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Grid Table 1 Light"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Grid Table 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Grid Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Mention"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Smart Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hashtag"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Unresolved Mention"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536859905 -1073732485 9 0 511 0;}
@font-face
	{font-family:"Lucida Grande";
	panose-1:2 11 6 0 4 5 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Times;
	panose-1:0 0 5 0 0 0 0 2 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1342185562 0 0 415 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:#0563C1;
	mso-themecolor:hyperlink;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:#954F72;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Lucida Grande";
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Lucida Grande";}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
span.UnresolvedMention1
	{mso-style-name:"Unresolved Mention1";
	mso-style-noshow:yes;
	mso-style-priority:99;
	color:#605E5C;
	background:#E1DFDD;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Balloon Text";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Lucida Grande";
	mso-ascii-font-family:"Lucida Grande";
	mso-hansi-font-family:"Lucida Grande";
	mso-bidi-font-family:"Lucida Grande";}
span.UnresolvedMention2
	{mso-style-name:"Unresolved Mention2";
	mso-style-noshow:yes;
	mso-style-priority:99;
	color:#605E5C;
	background:#E1DFDD;}
span.UnresolvedMention3
	{mso-style-name:"Unresolved Mention3";
	mso-style-noshow:yes;
	mso-style-priority:99;
	color:#605E5C;
	background:#E1DFDD;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:921137028;
	mso-list-type:hybrid;
	mso-list-template-ids:-1285637366 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l1
	{mso-list-id:1839881676;
	mso-list-type:hybrid;
	mso-list-template-ids:1761657132 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l1:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level3
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l1:level4
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l1:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level6
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l1:level7
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l1:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level9
	{mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
</style>
<![endif]-->
</head>

<body lang=EN-US link="#0563C1" vlink="#954F72" style='tab-interval:.5in'>

<div class=WordSection1>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Company:
Akebia Therapeutics, Inc.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Symbol:
</span><b style='mso-bidi-font-weight:normal'><span style='font-size:14.0pt;
font-family:Times'>AKBA<o:p></o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Date
of analysis: 4/25/19<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Price
at analysis date: $6.45<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>PT:
$19.46<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Additional commentary from Elle
Investments can also be read on Seeking Alpha.<o:p></o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:14.0pt;font-family:
Times'>AKBA: 1-Year Chart, May 2018 – April 2019<o:p></o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-family:Times;mso-no-proof:yes'><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_i1028" type="#_x0000_t75"
 style='width:468pt;height:90pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="AKBA%203E.fld/image001.png" o:title=""/>
</v:shape><![endif]--><![if !vml]><img width=468 height=90
src="AKBA%203E.fld/image001.png" v:shapes="Picture_x0020_2"><![endif]></span><span
style='font-family:Times'><o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-size:10.0pt;font-family:Times'>Source: Seeking Alpha<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>INVESTMENT THESIS:</span></b><span
style='font-family:Times'> <o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Commercialized
drug <span class=SpellE>Auryxia</span> (approved in the US for hyperphosphatemia
in adults with dialysis-dependent chronic kidney disease (DD-CKD) and iron
deficiency anemia (IDA) in adults with non-dialysis-dependent (NDD) CKD) has
blockbuster potential, but after several years on the market, annual sales are
only about $100M. However, they have another potential blockbuster candidate, <span
class=SpellE>vadadustat</span>, which is in several phase-3 trials around the
globe. The hope is that it can become the standard of care in the $6B+ market
for anemia due to CKD in adults with DD-CKD and NDD-CKD. Our valuation for <span
class=SpellE>vadadustat</span> alone justifies a position in AKBA.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>LIQUIDITY POSITION:</span></b><span
style='font-family:Times'> Good<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>As
of 4Q18, AKBA had cash of $322M. Additionally, AKBA is eligible to receive over
$150M in development and regulatory milestones from its collaboration partners.
As per the 4Q18 earnings call, management says that the cash runway should
extend into 3Q20, so the risk of dilution seems fairly low.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>COMMERCIAL PROSPECTS:</span></b><span
style='font-family:Times'> Very Good<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span class=SpellE><b
style='mso-bidi-font-weight:normal'><span style='font-family:Times'>Auryxia</span></b></span><b
style='mso-bidi-font-weight:normal'><span style='font-family:Times'> (ferric
citrate)<o:p></o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Value: not included in valuation<o:p></o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span class=SpellE><span
style='font-family:Times'>Auryxia</span></span><span style='font-family:Times'>
has been on the market in the US since late 2014 for hyperphosphatemia in
adults with dialysis-dependent (DD) CKD. In early 2018, it also began selling
for a second indication: iron deficiency anemia (IDA) in adults with
non-dialysis-dependent (NDD) CKD. <span class=SpellE>Auryxia</span> is also
marketed in Japan under the trade name <span class=SpellE>Riona</span> for the
improvement of hyperphosphatemia in patients with CKD (both DD and NDD).
Lastly, it was approved in the EU in 2015 for the control of hyperphosphatemia
in adult patients with CKD under the trade name <span class=SpellE>Fexeric</span>
(it is not marketed yet in the EU, as the company continues to explore third
party commercialization opportunities).<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Expectations
for <span class=SpellE>Auryxia</span> were very high, with some analysts
projecting peak sales of $1B+ in just the US alone. However, almost 5 full
years after launch, the annual run-rate remains at a paltry $100M, with AKBA’s
management unwilling to give any type of sales guidance as of 4Q18 (until they
become more familiar with the normalized growth rate). Licensing revenue from
Japan also remains at less than $2M per quarter, and the
inability/unwillingness of KERX’s past management to sign a commercialization
partner in the EU several years after approval does not instill much
confidence.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>While
we acknowledge the possibility of <span class=SpellE>Auryxia</span> being able
to differentiate itself in the newer IDA indication, the sales results thus far
are such that we have chosen to exclude <span class=SpellE>Auryxia</span> from
our valuation. <span style='mso-spacerun:yes'>   </span><o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span class=SpellE><b
style='mso-bidi-font-weight:normal'><span style='font-family:Times'>Vadadustat</span></b></span><b
style='mso-bidi-font-weight:normal'><span style='font-family:Times'>
(hypoxia-inducible factor prolyl hydroxylase inhibitor) (HIF-PHI)<o:p></o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Value: $2.3B<o:p></o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:14.0pt;font-family:
Times'>AKBA: Drug Development Pipeline<o:p></o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-family:Times;mso-no-proof:yes'><!--[if gte vml 1]><v:shape id="Picture_x0020_1"
 o:spid="_x0000_i1027" type="#_x0000_t75" style='width:468pt;height:252pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="AKBA%203E.fld/image002.png" o:title=""/>
</v:shape><![endif]--><![if !vml]><img width=468 height=252
src="AKBA%203E.fld/image002.png" v:shapes="Picture_x0020_1"><![endif]></span><span
style='font-family:Times'><o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-size:10.0pt;font-family:Times'>Source: AKBA website<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-size:10.0pt;font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span class=SpellE><span
style='font-family:Times'>Vadadustat</span></span><span style='font-family:
Times'> is currently in various phase-3 trials for anemia due to CKD in adults
with DD-CKD and NDD-CKD. AKBA has multiple licensing deals in place around the
globe for <span class=SpellE>vadadustat</span> that have already generated over
$200M in upfront payments. Additionally, these licensing deals provide for
significant assistance in completing the various phase-3 trials being run: over
$1B in potential regulatory and commercial milestones, and very generous
double-digit royalties on net sales—all of which validate the blockbuster
potential of <span class=SpellE>vadadustat</span>.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>The
reason AKBA’s collaborators were so interested in becoming partners is because <span
class=SpellE>vadadustat</span> has the potential to set a new oral standard of
care for this indication. Anemia due to CKD is currently treated by injectable
recombinant human erythropoiesis-stimulating agents (ESAs) such as Epogen
(epoetin alfa) and Aranesp (darbepoetin alfa), or blood transfusion. Global
sales of injectable ESAs in 2018 were about $6.1B. Though this figure covers
all uses, the vast majority of sales were for the treatment of anemia due to
CKD.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Injectable
ESAs can be very effective in raising hemoglobin levels. However, in addition
to requiring a subcutaneous or intravenous injection, they can cause serious
side effects such as thrombosis, stroke, myocardial infarction and death. These
safety concerns became evident starting around 2006, and have subsequently led
to a major reduction in the utilization of injectable ESAs. For example, from
2009 to 2013, it is estimated that the collective injectable ESA treatment rate
in NDD-CKD patients in the US decreased by approximately half. Because of this,
anemia is either not treated or inadequately treated in the majority of NDD-CKD
patients, leaving a high unmet need for a new treatment paradigm (pg. 9, 2018 10-K).<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>When
AKBA announced their expanded licensing deal with Otsuka in the EU, China, and
other territories, they valued the addressable market at $3.5B. For our
valuation, we therefore assume an addressable market size of $3.5B in both the
US and the International territories covered by the Otsuka agreement. We think
this is reasonable given that global sales of ESAs in 2018 were $6.1B, and
considering the fact that many patients with anemia due to CKD go untreated because
of the harmful side effects. <o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Below
you can see our peak sales estimates for just the Otsuka US and International
territories, as well as our valuation for <span class=SpellE>vadadustat</span>.
Our calculation involves the following assumptions:<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l1 level1 lfo2;
tab-stops:276.2pt'><![if !supportLists]><span style='font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:Times'>Addressable Otsuka
US and International market size $3.5B (in each territory)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l1 level1 lfo2;
tab-stops:276.2pt'><![if !supportLists]><span style='font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:Times'>50% gross-to-net
reduction (2019 guidance for <span class=SpellE>Auryxia</span> gross-to-net
reduction)<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l1 level1 lfo2;
tab-stops:276.2pt'><![if !supportLists]><span style='font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:Times'>20% International
royalty rate to AKBA on net sales<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l1 level1 lfo2;
tab-stops:276.2pt'><![if !supportLists]><span style='font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:Times'>97% gross margin<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l1 level1 lfo2;
tab-stops:276.2pt'><![if !supportLists]><span style='font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:Times'>$250M in
commercialization costs<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l1 level1 lfo2;
tab-stops:276.2pt'><![if !supportLists]><span style='font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:Times'>21% tax rate<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l1 level1 lfo2;
tab-stops:276.2pt'><![if !supportLists]><span style='font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:Times'>Target P/E of 5<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l1 level1 lfo2;
tab-stops:276.2pt'><![if !supportLists]><span style='font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-family:Times'>No impact from
potentially dilutive securities (given the outstanding share count of 117M, the
impact will not be too material)<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>To
be conservative, we have only included the potential commercial milestones from
Otsuka, even though AKBA could also receive up to $175M from MTPC (for Japan and
other Asian countries) and $25M from <span class=SpellE>Vifor</span> (for sales
to select dialysis clinics and third-party dialysis organizations in the US).
Also, our choice of $250M in commercialization costs for the US territory might
seem a bit high, but we prefer to err on the side of caution. We feel confident
saying that AKBA’s share of <span class=SpellE>vadadustat</span> is worth
somewhere around $2.3B, which equates to a PT of $19.46/share, representing
202% upside. <o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:14.0pt;font-family:
Times'>AKBA: <span class=SpellE>Vadadustat</span> US And International Peak
Sales Estimates In Otsuka Territories </span></b><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>($M)</span></b><b style='mso-bidi-font-weight:
normal'><span style='font-size:14.0pt;font-family:Times'><o:p></o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:14.0pt;font-family:
Times'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-family:Times;mso-no-proof:yes'><!--[if gte vml 1]><v:shape id="Picture_x0020_5"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:468pt;height:85pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="AKBA%203E.fld/image003.png" o:title=""/>
</v:shape><![endif]--><![if !vml]><img width=468 height=85
src="AKBA%203E.fld/image003.png" v:shapes="Picture_x0020_5"><![endif]></span><span
style='font-family:Times'><o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-size:10.0pt;font-family:Times'>© 2019 Elle Investments. All rights
reserved.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:14.0pt;font-family:
Times'>AKBA: <span class=SpellE>Vadadustat</span> Valuation Based On Sales,
Licensing Revenue, and Commercial Milestones from Otsuka US And International
Territories </span></b><b style='mso-bidi-font-weight:normal'><span
style='font-family:Times'>($M)</span></b><b style='mso-bidi-font-weight:normal'><span
style='font-size:14.0pt;font-family:Times'><o:p></o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-family:Times;mso-no-proof:yes'><!--[if gte vml 1]><v:shape id="Picture_x0020_7"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:468pt;height:292pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="AKBA%203E.fld/image004.png" o:title=""/>
</v:shape><![endif]--><![if !vml]><img width=468 height=292
src="AKBA%203E.fld/image004.png" v:shapes="Picture_x0020_7"><![endif]></span><span
style='font-family:Times'><o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-size:10.0pt;font-family:Times'>© 2019 Elle Investments. All rights reserved.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>CONCLUSION:</span></b><span
style='font-family:Times'> <o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>AKBA
has continued to drift since the merger with KERX was announced in mid-2018. We
see this as a buying opportunity. While sluggish sales of <span class=SpellE>Auryxia</span>
do not currently offer very much to be hopeful for (and are partially
responsible for the downward drift), the value of <span class=SpellE>vadadustat</span>
alone is compelling. The solid cash position, along with the potential for <span
class=SpellE>vadadustat</span> to disrupt the $6B+ market for anemia due to CKD,
makes AKBA a strong buy. Our PT is $19.46/share, offering 202% upside.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>GLOSSARY:<o:p></o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>CKD:
chronic kidney disease<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>DD:
dialysis-dependent<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>ESA:
erythropoiesis-stimulating agent<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>IDA:
iron deficiency anemia<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>NDD:
non-dialysis-dependent<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>QOQ:
quarter-over-quarter<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Disclaimer: The Elle Investments
portfolio is managed utilizing a “<span class=SpellE>quantamental</span>”
approach where each position, while based on Fundamentals Analysis, is sized as
part of a large quantitative portfolio. The commentary presented here is for
research purposes and is not to be taken as investment advice. Readers are
expected to perform their own due diligence and/or hire an investment
professional prior to entering/exiting positions. Published research ideas are
related to the specific market price and publicly available information at the
time of article submission. Elle Investments will enter/exit positions without notice.<o:p></o:p></span></i></p>

</div>

</body>

</html>
